UNSPSC 51383802: Naproxcinod

This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H21NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, V24GR4LI3I chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 4-(nitrooxy)butyl ester, (.alpha.s)- but generally known as naproxcinod, which bears US NIH Compound Identifier 9884642. European Medicines Agency schedules Naproxcinod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30968.

UNSPSC 51383802 Naproxcinod is a Commodity code that in recent state and local activity covers the procurement of pharmaceutical products and drug-management systems rather than the specific anti-inflammatory agent the code name suggests. State and local governments are soliciting naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances administering on behalf of participating state and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance). The code captures a mix of spot purchases for immediate community health needs and longer-term framework agreements serving multiple jurisdictions simultaneously.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas HHS Commission posted Request for Information HHS0017013 on April 3, 2026, to assess vendor capability for implementing a direct-to-manufacturer prescription program serving self-insured state employee health plans outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, issued RFP S1070000015802 on January 20, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026. Vendors responding to MMCAP must maintain contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson) and comply with cGMP certification, Drug Supply Chain Security Act requirements, and comprehensive insurance coverage including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability.